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Introduction
Glaucoma is a leading cause of irreversible blindness 
worldwide and is associated with characteristic damage to 
the optic nerve and patterns of visual field loss due to reti-
nal ganglion cell (RGC) degeneration. Intraocular pressure 
(IOP) is regarded as the major risk factor. There are esti-
mated to be over 60 million people worldwide with glau-
comatous optic neuropathy of which 8.4 million are blind 
[172]. The global incidence of glaucoma is anticipated to 
increase to 76 million by 2020 and 111.8 million by 2040 
[172]. Glaucoma is an umbrella term encompassing various 
subtypes of the condition, but the structural damage to the 
optic nerve is common throughout. The formal definition of 
clinical glaucoma as suggested by Casson et al. is [22]:
“a group of ocular disorders of multifactorial aeti-
ology united by a clinically characteristic optic neu-
ropathy with potentially progressive, clinically visible 
changes at the optic nerve head (ONH), comprising 
focal or generalized thinning of the neuroretinal rim 
with excavation and enlargement of the optic cup, 
representing neurodegeneration of retinal ganglion 
cell axons and deformation of the lamina cribrosa; 
corresponding diffuse and localized nerve-fibre-bun-
dle pattern visual field loss may not be detectable in 
early stages; while visual acuity is initially spared, 
progression can lead to complete loss of vision; the 
constellation of clinical features is diagnostic”
Glaucoma is principally divided into open-angle or 
angle-closure subtypes, where angle closure refers to the 
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presence of appositional or synechial iridotrabecular con-
tact resulting in the obstruction of the trabecular mesh-
work and elevated IOP [46]. Both open-angle glaucoma 
and angle-closure glaucoma can be further subdivided 
into primary or secondary diseases, where primary refers 
to the observation of characteristic optic neuropathy in the 
presence of normal or elevated IOP with no distinguish-
able pathological cause. Secondary disease refers to an 
elevated IOP with an identifiable pathological cause, such 
as inflammation, trauma, neovascularisation, pigment dis-
persion, and pseudoexfoliation [22]. Finally, primary open-
angle glaucoma (POAG) can be arbitrarily further subdi-
vided depending on the IOP status of the patient. Normal 
tension glaucoma (NTG) was a commonly used term that 
has fallen out of favour recently. NTG refers to POAG, 
where patients exhibit a normal IOP (IOP typically <97.5 
percentile of population, <21 mmHg) versus POAG with 
an elevated IOP (IOP typically >97.5 percentile of popu-
lation), although this distinction is arbitrary and may not 
be clinically relevant [57]. It is also important to note that 
not all high IOP causes damage to the optic nerve, a con-
dition known as ocular hypertension [93]. This reinforces 
the theory that although IOP is currently the only modifi-
able risk factor in glaucoma, there are other factors influ-
encing the progression of RGC loss. IOP reduction, even 
if the presenting IOP is normal, is still the principle way of 
managing this condition and is very effective with a 20 % 
reduction in pressure, reducing the risk of progression by 
50 % [93].
A recent systematic review and meta-analysis by Tham 
et al. estimates a global glaucoma prevalence of 3.54 % of 
the population aged between 40 and 80 years of age [172]. 
In this study, the prevalence of glaucoma subtypes was 
found to vary by region and ethnicity, with the incidence of 
POAG varying between 4.20 % (Africa) and 2.31 % (Asia), 
and primary angle closure glaucoma varying between 
1.09 % (Asia) and 0.26 % (North America). Additional risk 
factors for POAG identified using Bayesian Meta-Regres-
sion Modelling include: age, gender, and environment. A 
summary of the proposed POAG risk factors is presented 
in Table 1.
The diagnosis of glaucoma is presently achieved using 
a combination of both functional and structural assess-
ments. The standard automated perimetry is primarily used 
to assess functional deficits in glaucoma patients, while 
structural diagnostic tools are principally based on the 
quantification of retinal nerve fibre layer (RNFL) thick-
ness changes by optical coherence tomography (OCT) and 
disc tomography (confocal laser-scanning tomography) 
to assess structural changes at the site of the optic nerve 
head (ONH). Clinical assessment of the optic disc using 
slit lamp examination is not surpassed by recent advances 
in structural imaging techniques. Slit lamp biomicroscopy 
is required to assess the colour or pallor of the disc, disc 
haemorrhages, and factors associated with secondary glau-
comas, such as neovascularisation of the disc, retina, iris 
and drainage angle, uveitis, pseudoexfoliation, pigment 
dispersion, primary or secondary iris transillumination, 
trauma, and gonioscopic assessment of the drainage angle.
IOP, presently the only modifiable risk factor for glau-
coma, is assessed using tonometry devices. The gold stand-
ard is Goldman applanation tonometry (GAT), but other 
devices exist and are used in optometric practice and in 
research settings, such as non-contact tonometry (e.g. Pul-
sair), rebound tonometry, and ocular pulse analyser [127]. 
An increasingly recognised limitation of IOP measurement 
by tonometry is that a thicker central cornea, as measured 
by ultrasound pachymetry, leads to a higher measured IOP 
than is present, whereas a thinner central cornea underesti-
mates the true IOP [107].
A major drawback of current approaches to glaucoma 
diagnosis includes the inability to positively diagnose glau-
coma before considerable damage to the retina has already 
occurred. Although RGC apoptosis has been identified as 
the earliest form of cell death in glaucoma, it is estimated 
that up to 40 % of RGCs are lost before field defects can be 
detected using the standard clinical tests [94].
The eye offers the unique opportunity to non-inva-
sively image structures of the central nervous system. This 
review outlines recent developments in our understand-
ing of the underlying mechanisms of glaucoma pathol-
ogy and explores recent advances towards exploiting these 
findings to develop novel tools for the early diagnosis of 
glaucoma, including an overview of recent advances in 
retinal and brain-imaging technologies. The role of Mül-
ler cells and microglia in glaucoma pathology has recently 
been reviewed elsewhere [161] and, therefore, considered 
beyond the scope of this article.
Mechanisms of RGC and axonal death
RGC loss predominantly occurs by apoptosis
Loss of RGCs has been identified as the earliest form of 
cell death in glaucoma, and reduction in RGC function 
is ultimately considered responsible for visual field loss 
[144]. The human retina contains approximately 1.5 million 
RGCs [119] with an estimated rate of RGC loss of 0.4 % 
per year due to normal physiological ageing, increasing to 
4 % per year in glaucoma patients [31]. RGC death in glau-
coma is thought to predominantly occur through apoptosis, 
although other forms of cell death do occur [154].
Apoptosis describes a process of controlled cell death, 
rather than necrosis, which describes disordered and acci-
dental cell death [63]. Apoptosis is a regulated process of 
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Table 1  Overview of identified risk factors for POAG
Parameter Trend Key references
IOP elevation Increased incidence and prevalence. Increased rate of progression (RoP); elevated IOP com-
pared to normal IOP—Canadian glaucoma study odds ratio (OR) 1.19, European glaucoma 
prevention study OR 1.12
Miglior et al. (2007)
Chauhan et al. (2008)
Gordon et al. (2002)
Age Increased incidence and prevalence; Hispanics and people of European ancestry showed a 
steeper increase in POAG prevalence with age compared with African and Asian populations
Leske et al. (2008)
Friedman et al. (2007)
Race Increased incidence and prevalence of POAG in African (highest prevalence worldwide, 4.2 % 
of African population), Afro-Caribbean and coloured American population
Friedman et al. (2007)
Inheritance Increased incidence and prevalence
First degree relative with glaucoma increases POAG risk ten-fold
POAG exhibits minor but significant heritability (twin study)
Leske et al. (2008)
Le et al. (2003)
Gordon et al. (2002)
Wolfs et al. (1998)
Gender Increased incidence and prevalence in men (OR 1.36) Tham et al. (2014)
Living area Higher incidence for people living in urban habitation areas than those in rural areas (OR 1.58)
Myopia Increased RoP, OR of 1.65 between low myopia (myopia up to -3D) and glaucoma and OR of 
2.46 between high myopia (≤-3D myopic) and glaucoma
Marcus et al. (2011)
Cornea thickness Increased incidence and prevalence in patients presenting with a thin cornea thickness, African 
American participants had a thinner central corneal measurement (554.9 ± 38.5 µm) than 
other participants (578.3 ± 36.5 µm)
Leske et al. (2008)
Gordon et al. (2002)
Pseudoexfoliation syn-
drome (PES)
Increased incidence and prevalence
Strong risk factor for POAG progression
Varies by ethnicity and geographic location (high prevalence in Scandinavian populations)—
patients with bilateral PES tend to be older and have a higher incidence of glaucoma or 
ocular hypertension when compared to patients with unilateral involvement
Increased incidence and prevalence in men and patients between 52–64 (0.6 %) and 75–85 
(5 %) years old
Increased RoP due to higher fluctuations in IOP levels and reduced response to topical therapy
Le et al. (2003)
Kozart et al. (1982)
Leibowitz et al. (1980)
Cup–disc ratio Increased incidence in larger vertical cup–disc ratio > 0.7 and larger horizontal cup–disc ratio, 
cup-disc ratio has to be corrected for disc size- highest diagnostic power compared to other 
optic disc parameters for separating healthy subjects from preperimetric glaucoma patients 
varies with race-African Americans had a larger vertical cup–disc ratio (0.45 ± 0.18) com-
pared with other participants (0.37 ± 0.20)
Gordon et al. (2002)
Le et al. (2003)
Blood pressure abnor-
mality
Increased incidence and prevalence with low systolic pressure, increased severity with diurnal 
pressure fluctuations and lower diastolic blood pressure, especially during night time
Increased RoP in patients taking hypertensive medication in the evening—evening rhythm is 
associated with significantly lower perfusion pressures at night
Leske et al. (2008)
Obstructive sleep 
apnoea syndrome 
(OSAS)
Increased incidence and prevalence (odds ratio 1.41–1.96) Shi et al. (2015)
Diabetes Diabetes patients showed a higher prevalence than healthy patients (odds ratio 1.48), risk of 
glaucoma increased by 5 % for each year since diagnosis
Zhao et al. (2015)
Zhou et al. (2014)
Medication Increased RoP and incidence when using systemic calcium channel blockers (1.8 fold higher 
risk)
Müskens et al. (2007)
Migraine Higher incidence and prevalence in normal tension glaucoma (21.4 %) compared to POAG 
(13.1 %) and PACG (10.1 %)
Gordon et al. (2002)
Gramer et al. (2015)
Cerebrovascular 
accident
Increased RoP, Blue mountain eye study—glaucoma patients had a non-significant increased 
risk of cardiovascular death (relative risk RR 1.46), increased cardiovascular mortality in 
glaucoma patients <75 years (RR 2.78)
Gordon et al. (2002)
Lee et al. (2006)
Metabolic syndrome 
(includes obesity, 
smoking, alcohol 
intake)
Increased severity in patients with obesity showing excessive orbital fat and increased blood 
viscosity which may increase episcleral venous pressure and reduce aqueous outflow
Increased RoP in women showing a low body mass index—suggested to be a result of the 
relationship between BMI and cerebral spinal fluid pressure
Mori et al. (2000)
Ramdas et al. (2011)
Zeevaart et al. (2009)
Berdahl et al. (2012)
Age-related macular 
degeneration
Increased prevalence in 4–40 % of glaucoma patients in predominantly Caucasian populations Le et al. (2003)
Peräsalo et al. (1994)
Tarkkanen et al. (2008)
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cell death leading to chromatin condensation, DNA frag-
mentation, oxidative damage, and autophagic degeneration, 
commonly proceeding through either extrinsic or intrinsic 
caspase-dependent pathways [50]. Due to the complex and 
multifactorial nature of glaucoma (Table 1), multiple mech-
anisms are thought to contribute to RGC loss. Observations 
that axotomy precedes RGC soma loss by a period of sev-
eral days in rodent models of axotomy and IOP elevation 
using the retrograde label Fluorogold have long hinted that 
changes at the level of the RGC axon precede apoptotic 
degeneration of the RGC soma [15]. More recent support 
for this view was presented by Calkins, who in summaris-
ing the results of several rodent studies using the acute IOP 
Morrison’s model of ocular hypertension found that axonal 
degeneration typically occurs at a 2–3-fold greater extent 
than RGC soma loss and exhibits a stronger positive cor-
relation with IOP exposure [18].
Evidence to support the theory of RGC loss as a result 
of axonal transport failure in glaucoma was first observed 
in experimental monkey models of IOP elevation by Ander-
son and Hendrickson, who identified the site of the lamina 
cribrosa as the primary site of transport dysregulation [3]. 
Downregulation of retrograde (brain-to-retina) axonal 
transport in response to anterior chamber cannulation-
induced IOP elevation in the rat was reported by Johansson 
et al. [83]. Experimental data to demonstrate anterograde 
(retina-to-brain) axonal transport dysregulation was later 
described in the murine transgenic DBA/2 glaucoma model 
and microbead occlusion model of raised intraocular pres-
sure [33]. A more comprehensive mini-review outlining 
the history of axonal transport dysregulation was recently 
published [51]. Several mechanisms have been proposed 
to describe the events resulting in axonal transport dys-
regulation leading to RGC axonal degeneration and soma 
death, an overview of which is provided in the following 
sub-sections.
Mechanical theory of glaucoma progression
The mechanical theory of glaucoma progression suggests 
that elevated IOP leads to the compression of the nerve 
fibre bundle, primarily at the site of the Elschnig’s ring and 
the lamina cribrosa, causing a simultaneous discontinuity 
of anterograde and retrograde axoplasmic transport [193]. 
One mechanism by which this was thought to lead to sub-
sequent RGC degeneration and apoptosis induction is via 
the inhibition of the retrograde transport of Neurotrophic 
Factors (NFs), such as the Brain Derived Neurotrophic Fac-
tor (BDNF) and Neurotrophins 4/5 (NT4/5), from the supe-
rior colliculus to RGC soma [84], despite an early compen-
satory period of increased production of BDNF mRNA by 
RGCs in optic nerve injury models [62]. Further support for 
the involvement of neurotrophic factor deprivation in RGC 
apoptosis was found when exogenous administration of NF 
proteins, including Nerve Growth Factor (NGF), Ciliary 
neurotrophic factor (CNTF), and BDNF, protected RGCs 
from apoptosis in vitro [85] and in vivo models of disease 
[147]. BDNF stimulates various retinal signalling pathways 
on the activation of its target TrkB receptor, including the 
extracellular signal-regulated kinases 1/2 (Erk1/2) and the 
phosphatidylinositol-3 kinase (PI-3 K)/Akt pathways. Both 
play a major role in RGC loss in glaucoma [132].
Criticisms of the mechanical theory of glaucoma pro-
gression include a lack of correlation between IOP and 
visual field loss in some patient subsets. For example, 
racial differences in glaucoma incidence are reported 
despite similar IOP profiles. In addition, a gender dispar-
ity in the prevalence of NTG is observed despite similar 
IOP profiles [53]. A possible explanation for these observa-
tions can be found in consideration of the biomechanical 
structure of tissues at the site of the sclera and ONH. This 
paradigm suggests that variations in the biomechanical 
properties of these tissues may contribute to the variance 
in susceptibility to IOP-induced deformation of these tis-
sues and glaucomatous visual field loss [43]. Clinical sup-
port for ONH and lamina cribrosa deformation in glaucoma 
patients includes a recent study using spectral-domain opti-
cal coherence tomography to visualise the ONH of 173 
eyes (from 88 glaucoma patients and 20 normal subjects) 
at 4 month intervals for a mean duration of 5.3 years [190]. 
The study reported that both the ONH and anterior lamina 
cribrosa surfaces were displaced in a significant portion of 
glaucoma patients and the magnitude of this change was 
related to patient age and average IOP during follow-up. A 
recent criticism of this approach, however, is that studies 
such as these assume ONHs that possess an atypical sensi-
tivity to IOP also have atypical characteristics, which may 
not necessarily be the case [181]. This suggests that it may 
be difficult to use eye-specific biomechanical properties as 
predictors of IOP sensitivity and glaucoma susceptibility in 
isolation.
Further limitations of the mechanical theory of glau-
coma progression were identified when observations from 
animal studies suggested differences in the rate of inhi-
bition of anterograde and retrograde axonal transport in 
RGCs. An earlier onset and greater extent of anterograde 
transport dysregulation was reported in the microbead 
occlusion and DBA/2 J murine model of glaucoma [33, 
39]. A possible solution to the discrepancy in anterograde/
retrograde axonal transport dysfunction can be found when 
consideration is paid to the differences in energy require-
ment for each of these processes. Anterograde axonal trans-
port is dependent on kinesins which are reported to utilise 
ATP less efficiently than the retrograde transport protein 
dynein, which can change its step-size dependent on ATP 
availability and so better maintain function in an energy 
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scarce environment [116]. The dependence of axonal trans-
port processes on energy availability suggests a role for 
mitochondrial dysfunction in RGC axonal degeneration 
inviting an ischemic theory of glaucoma progression.
Ischemic theory of glaucoma progression
A blood perfusion deficit is the main component of the 
ischemic theory of glaucoma which states that hemody-
namic alterations may act independently from, or in con-
junction with, raised IOP to cause damage at the site of the 
ONH [53]. The ischemic theory of glaucoma has also been 
suggested to play a fundamental role in the pathogenesis of 
NTG, with reports of patients with systemic vascular dis-
orders (such as atherosclerotic ischemic stroke) being at 
significantly greater risk of glaucomatous cupping of the 
optic disc and bilateral NTG development [98]. In addi-
tion, patients with primary vascular dysregulation, which 
describes a condition associated with sudden vasoconstric-
tion in response to environmental or emotional stimuli 
in the extremities and the retina, is also associated with 
increased risk of NTG [54].
Further evidence to support the ischemic theory of glau-
coma progression stems from recent developments in non-
invasive measurement of ocular blood flow (OBF) which 
can be achieved with increasing accuracy using functional 
OCT [171]. A significant reduction in OBF and ocular per-
fusion pressure in POAG patients is reported versus con-
trols using these techniques [171]. Reduced ocular blood 
flow is purported to result in RGC loss via induction of a 
recurrent mild ischemic injury leading to chronic oxidative 
stress and excitotoxicity [129] or alternatively, by sensitis-
ing RGCs to ordinarily well-tolerated secondary insults, 
such as glutamate, nitric oxide, and phototoxicity [135]. 
These insults act to impede mitochondrial function, the 
effects of which are most pronounced at the site of unmy-
elinated RGC axons at the ONH which, due to the reduced 
efficiency of signal transduction of unmyelinated axons, 
have one of the greatest energy demands in the body, mani-
festing as a high mitochondrial density at this location 
[103].
The role of mitochondria dysfunction as the cause of 
RGC axonal transport dysregulation also offers an explana-
tion for the age-dependent increase in glaucoma risk due 
to reduced mitochondrial efficiency [16] and the increased 
incidence of genetic mutations associated with mitochon-
drial dysfunction in POAG patients [10]. Declining mito-
chondrial function with age is thought to increase suscepti-
bility to additional stressors, such as elevated IOP [33], and 
has been suggested as a potential mechanism to explain the 
lack of positive correlation between the clinical correlates 
of RGC loss and extent of elevated IOP [32]. Mitochon-
dria are highly dynamic organelles which undergo fusion 
and fission events. They help to mitigate stress by diffus-
ing the contents of partially damaged mitochondria and by 
facilitating apoptosis during high levels of cellular stress, 
respectively [198]. Histological observations reveal induc-
tion of mitochondrial fission and optic atrophy 1 (OPA1) 
release in murine models of glaucomatous optic neuropa-
thy [91]. OPA1 regulates mitochondrial fusion and main-
tenance of cristae structure. Mutations in this protein are 
responsible for dominant optic atrophy [1], and reduced 
expression is reported in POAG patients due to increased 
susceptibility to stress-induced mitochondrial dysfunction 
[13]. Upregulation of OPA1 expression has been found to 
protect RGC loss in glaucomatous DBA/2 J mice, suggest-
ing that this protein may provide a therapeutic target for the 
treatment of POAG [90].
Dysregulation of RGC axonal transport processes is 
thought to result in RGC death through dysregulation of 
calcium homeostasis, resulting in increases in cytoplasmic 
calcium concentrations culminating in increased oxida-
tive stress, calpain-mediated cytoskeletal degradation, and 
caspase-dependent apoptosis induction [32]. Calcium chan-
nel blocker therapies, including nimodipine, brovincamine, 
and nilvadipine, have been suggested to have beneficial 
effects on visual function in both animal models and small 
scale trials in glaucoma patients, however, differentiating 
neuroprotective and vasodilating effects of these agents 
has proven difficult with larger multi-centre trials of these 
agents required [4].
Autophagy dysregulation in glaucoma
Autophagy describes the orderly self-degradation and recy-
cling of unwanted or dysfunctional cellular components 
and is used by terminally differentiated cells to manage 
their cytoskeletal and organelle turnover [101]. Autophagy 
can be upregulated in response to cellular stress [102] and 
dysregulation of this process is increasingly associated with 
neuropathological conditions, including Alzheimer’s and 
Parkinson’s diseases [134]. In glaucoma models, an appar-
ent upregulation of autophagy (via increased observance of 
autophagosomes) is reported in RGC soma [38], and dys-
regulation of autophagic flux is reported in RGC axons in 
response to downregulation of anterograde axonal transport 
in the murine DBA/2 J glaucoma model [101].
As a therapeutic target for glaucoma treatment, the role 
of autophagy in RGC death remains controversial, with 
both inhibitors (3-methyladenine) and inducers (Rapamy-
cin) reported to elicit neuroprotection in the same rodent 
glaucoma model [136, 169]. A possible explanation for this 
discrepancy is that Rapamycin acts on pathways in addition 
to autophagy modulation such as downregulation of TNF-α 
[169]. An alternative explanation suggests, while the inhibi-
tion of autophagy at the site of the RGC soma can prevent 
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apoptosis induction late in glaucoma progression, induc-
ers of autophagy, such as Rapamycin, may act to upregu-
late autophagy at the site of the RGC axons and so elicit a 
neuroprotective action provided that they are administered 
early in the disease process [130]. Once this controversy is 
resolved, favourable modulation of  autophagy to preserve 
RGC function could provide a novel therapeutic target for 
the treatment of glaucoma.
Amyloid beta and tau in early glaucoma pathology
Amyloid beta (Aβ) is the major constituent of senile 
plaques in Alzheimer’s disease (AD), caused by the abnor-
mal processing of Amyloid Precursor Protein (APP). Reti-
nal deposition of Aβ is increasingly thought to contribute 
to the ocular abnormalities reported in AD patients [146]. 
Age-dependent accumulation of Aβ in RGCs has been sug-
gested to contribute to glaucoma pathology, and anti-Aβ 
therapies have been identified as a therapeutic target to 
prevent RGC degeneration [68]. These data, coupled with 
reports of an increased incidence of AD among glaucoma 
patients [113], have led to the suggestion that glaucoma 
could be described as a type of ocular AD [123].
Aβ production in glaucoma can occur as a result of 
caspase-3-mediated abnormal APP processing [124], and 
reduced levels of Aβ1-42 and increased levels of Tau are 
found in the vitreous of glaucoma patients versus age-
matched controls, a pattern consistent with that found in 
the Cerebral Spinal Fluid (CSF) of patients with AD [197]. 
More recent observations suggest that Aβ1-42 is upregulated 
in the RNFL at the site of the ONH in a monkey model 
of chronic ocular hypertension [81]. This is of interest as 
Aβ is well documented to interrupt both intracellular cal-
cium homeostasis [166] and anterograde axonal transport 
processes [21] in AD, and a similar pathology may occur in 
glaucomatous RGC degeneration and explain the increased 
susceptibility of AD patients to glaucoma [12].
Disruption of intracellular calcium homeostasis by Aβ in 
neurons during AD can occur via a number of processes, 
such as increasing plasma membrane permeability via the 
formation of calcium permeable-pores [157]. Aβ-mediated 
disruption of anterograde axonal transport in hippocampal 
neurons can occur directly via activation of actin poly-
merisation by Ras homolog gene family member A (RhoA) 
[176], or glycogen synthase kinase-3β (GSK-3β) signalling 
[36].
GSK-3β is an inhibitor of fast anterograde axonal trans-
port implicated in glutamate-induced excitotoxicity [27]. 
Inhibition of GSK-3β-mediated activation of dynamin-
related protein 1 (Drp-1) has recently been demonstrated to 
reduce Aβ-induced mitochondrial fission and apoptosis in 
culture and murine models of AD [194]. In the retina, an 
RNAi screen has recently identified GSK-3β as a regulator 
of Drp-1, inhibition of which was recently observed to 
preserve RGC axon integrity in murine glaucoma models 
[100]. While inhibitors of GSK-3β have been identified as 
an important strategy for the treatment of CNS disorders 
including AD [49], to date, there are few studies inves-
tigating whether these molecules could be of benefit for 
the treatment of glaucoma. Elevated levels of RhoA are 
reported in the ONH of human eyes with glaucoma [66], 
and Rho kinase (ROCK) inhibitors are increasingly recog-
nised as a promising therapeutic strategy for the treatment 
of glaucoma, indicating shared pathology [184]. In addition 
to the well-established IOP-modulating activity of these 
agents, ROCK inhibitors have been found to promote RGC 
axonal regeneration in both murine and feline models of 
optic nerve crush, a subject recently reviewed by Van de 
Velde et al. [177].
A downstream effect of Aβ-mediated activation of 
GSK-3β in hippocampal neurons is the tau hyper-phospho-
rylation, which can stimulate the release of kinesin bound 
cargos so reducing the efficiency of anterograde axonal 
transport [92]. A histological study of 19 enucleated human 
eyes found a significant age-dependent increase in gan-
glion cell layer Tau protein using a phosphorylation state-
independent antibody [105]. A further human study of 11 
surgical glaucomatous eyes revealed that Tau is ordinarily 
present in both the inner nuclear and inner plexiform reti-
nal layers, but concentrations are diminished in glaucoma 
patients versus age-matched controls [70]. The same study 
suggests that the concentrations of abnormally phosphoryl-
ated (AT8) Tau were elevated in secondary angle closure 
glaucomatous but not in six POAG eyes, which may imply 
the extent of Tau hyper-phosphorylation correlates with 
disease severity. Both Tau and hyper-phosphorylated Tau 
have been suggested to influence axonal transport processes 
in cortical neurons via a number of processes [186]. For 
example, upregulation of Tau is documented to selectively 
impede anterograde axonal transport of APP and organelles 
due to the ten-fold higher affinity of Tau for kinesin than 
dynein [41]. Murine studies have suggested that downregu-
lation of Tau could provide an attractive therapeutic target 
for the prevention of Aβ-induced dysregulation of axonal 
transport [182].
The role of trans‑lamina cribrosa pressure difference 
in glaucoma
An alternative explanation for the variability in response 
to IOP elevation and extent of glaucomatous RGC dam-
age is that IOP does not wholly describe the pressure 
situation at the ONH [87]. The change in IOP relative to 
orbital cerebral spinal fluid pressure (CSFP), the so-called 
trans-lamina cribrosa pressure difference (TLPD) or a 
change in the time-dependent relationship between the 
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pulse-synchronous changes in IOP and orbital CSFP, has 
been suggested to provide a more accurate description of 
the pressure situation at the ONH [87]. There is growing 
clinical evidence to support the hypothesis that CSFP and 
TLPD play an important role in glaucoma pathology. This 
hypothesis may also explain the increased incidence of 
glaucoma in patients with a history of migraine (Table 1), 
as elevated intracranial pressure is associated with this con-
dition [164]. A recent literature review and meta-analysis 
comprising five papers and a total of 396 patients by Siaud-
vytyte et al. revealed that CSFP is elevated in glaucoma 
patients compared to healthy subjects and TLPD is related 
to changes in optic disc structure in patients with high-
tension glaucoma [162]. The authors caution, however, that 
further experimental investigations and longitudinal pro-
spective clinical studies are required to overcome the meth-
odological weaknesses of the current studies, concerns ech-
oed by Pircher and Killer [138]. Since this time, the Beijing 
intracranial and intraocular pressure (iCOP) reported a 
positive association between TLPD (calculated from LP-
CSFP) and visual field defects in POAG patients [77] and 
a population-based study from the Korean National Health 
and Nutrition Examination Survey (KNHANES) found that 
TLPD (calculated from estimated CSFP values) was signif-
icantly associated with HT-NTG [104].
Further support for a role of CSFP and TLPD in glau-
coma pathology is found in animal models. For example, 
a study by Yang et al. in a monkey model demonstrated 
optic neuropathy in response to chronic reduction in CSFP 
despite normal IOP [195]. Further evidence to support this 
view was recently presented by Hou et al., who found, 
in canines, that TLPD became uncoupled once CSFP is 
reduced below a critical threshold [77]. This, coupled with 
reports that CSFP naturally declines with age, offers an 
attractive explanation for the efficacy of IOP-modulating 
therapies for the treatment of NTG and suggests that the 
management of CSFP in addition to IOP should be consid-
ered for a more effective glaucoma treatment strategy [55]. 
Large-scale clinical application of TLPD measurements is, 
however, presently limited by the invasive nature of LP-
CSFP monitoring and the erroneous assumption that CSFP 
is uniform between the spinal column and optic nerve suba-
rachnoid space (SAS) [97]. Non-invasive techniques for 
determining CSFP and TLPD are presently in development 
[163].
Two mechanisms have been proposed to describe the 
influence of CSFP and TLPD on glaucoma pathology. The 
first of which suggests that an abnormal CSFP leads to 
similar mechanical deformation of the ONH as has previ-
ously been reported for elevated IOP [86]. This hypothesis 
is contested on grounds including that the rigid structure of 
the lamina cribrosa will resist bowing at TLPDs of clini-
cally relevant magnitude [74]. A second mechanism is that 
the dysregulation of CSF hydrodynamics, manifesting as 
elevated CSFP and resulting in accumulation of toxic com-
pounds at the site of the ONH, leads to RGC loss [189]. 
There has been a recent resurgence in interest in the role 
of CSF turnover in CNS disorders with the re-discovery 
of the paravascular pathway for CSF and interstitial fluid 
exchange in the brain, termed the glymphatic system [82]. 
Dysregulation of glymphatic mediated clearance of intersti-
tial solutes, including Aβ and Tau, has been suggested as a 
novel mechanism to explain the increased risk of dementia 
in patients after traumatic brain injury [80]. The dysregu-
lation of the production and clearance of cytotoxic com-
pounds, such as Aβ, coupled with recent postulations as 
to the existence of an ocular glymphatic system [40], has 
led to the development of a novel hypothesis for glaucoma 
pathology based on the reduction in CSF clearance from 
the SAS via ocular glymphatic dysregulation [189]. Thera-
peutic interventions to increase glymphatic clearance such 
as aquaporins agonists, which are currently under investi-
gation for the treatment of AD, may also be of interest for 
the treatment of glaucoma [174]. Finally, the recognition 
that Schlemm’s canal is a VEGF-c responsive vessel with 
lymphatic phenotype [5], coupled with the observation that 
the concentration of proteins implicated in cytotoxic pro-
cesses (inflammation, apoptosis, angiogenesis, and oxida-
tive stress) in the aqueous humour that are elevated in ocu-
lar disease [9] may suggest a role for aqueous outflow in 
the removal of cytotoxic compounds from posterior ocular 
tissues. This offers an alternative explanation why therapies 
to increase aqueous outflow may be more advantageous 
than those which act to reduce aqueous inflow [175].
The brain in glaucoma
The observation that glaucoma exhibits pathological simi-
larities with CNS neurodegenerative disorders, coupled 
with recent advancements in neuroimaging technologies, 
has led to a growth in interest in the effects of glaucoma 
on the visual pathway in the brain [72]. The human visual 
pathway is divided into two parts; the anterior visual path-
way is composed of the retina, optic nerve, and chiasm and 
lateral geniculate nucleus (LGN), while the posterior visual 
pathway comprises the optic radiations and visual cortex 
(Fig. 1a).
The lateral geniculate nucleus (LGN)
In humans over 90 % of RGC axons project to the LGN, a 
relay station which in turn projects its axons to the visual 
cortex via the optic radiation [200]. The remaining 10 % 
of RGCs project to brain structures, including the supe-
rior colliculus (eye-movement control), pretectal area (eye 
movement/pupillary reflex), accessory optic system nuclei 
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(optokinetic nystagmus), and the suprachiasmatic nucleus 
(circadian rhythm maintenance) [65]. Both brain hemi-
spheres possess an LGN which primarily receives informa-
tion from its contralateral visual hemifield and is typically 
organised into six distinctive layers; with the magnocellular 
cells (M-cells) in ventral layers (1 and 2) and parvocellu-
lar cells (P-cell) occupying the dorsal layers (3–6). Each 
layer of M- and P-cells is in turn separated by a layer of 
Koniocellular cells (K-cells), as shown in Fig. 1b [192]. M, 
P, and K cells of the LGN receive input from their respec-
tive M, P, and K RGCs, the M pathway is achromatic and 
displays high-frequency tuning and the P pathway exhibits 
chromatic sensitivity and high spatial resolution [2]. K cells 
are thought to comprise multiple classes which are sug-
gested to contribute short-wavelength chromatic and orien-
tation selectivity [192].
Cells in the LGN respond to visual response fields 
similar to those found in RGCs. There is approximately a 
one-to-one mapping of RGC output to LGN output in pri-
mates [73], thus there is close matching of receptive field 
characteristics. Typically, RGC axons from the ipsilateral 
eye synapse in layers 2, 3, and 5 of the LGN, while axons 
from contralateral eyes synapse in the first, fourth, and 
sixth layers [170]. Traditionally, the primary function of 
the LGN was thought to act as a gateway, relaying visual 
information from RGCs to the visual cortex [88]. More 
recent observations that retinal afferents constitute only 
10 % of LGN input with additional modulatory inputs 
from a variety of brain regions (including the striate 
cortex, the brain stem, and thalamic reticular nucleus), 
suggests that the LGN instead acts more like a gatekeeper, 
representing the first stage of the visual pathway, where 
cortical top-down feedback can influence visual process-
ing [122].
The primary visual cortex
The LGN output pathway begins with the projection of 
thalamocortical axons through the internal capsule to form 
broadly spreading fibres termed the optic radiations, which 
terminate in each hemispheres ipsilateral primary visual 
cortex in the occipital lobe (V1) [140]. As the optic radia-
tions leave the LGN, they are divided into the superior and 
inferior radiations. Inferior radiations project to inferior 
areas of the primary visual cortex, providing information 
regarding the superior visual field, while superior radia-
tions project to superior regions of the primary visual cor-
tex, supplying information on the inferior visual field [140]. 
LGN relay neurons from the M, P, and K layers remain seg-
regated throughout the optic radiation, projecting to distinct 
layers of V1 (layers 4Cα, 4Cβ, and 2/3, respectively [24]). 
In turn, each V1 transmits information via the ventral and 
dorsal stream to higher order centres in the visual cortical 
hierarchy (V2–V6). In addition to these feed-forward con-
nections, a series of direct reciprocal and cascading feed-
back processes enable neurons of the visual system to serve 
as adaptive processors, adopting different functional roles 
according to the task being executed [64].
Fig. 1  Overview of the human visual pathway. a Diagrammatic representation of the human visual pathway. b Overview of the structure of the 
lateral geniculate nucleus illustrating the organisation of magnocellular (M-cells), parvocellular (P-cell), and Koniocellular cells (K-cells)
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Techniques for monitoring retinal ganglion cell 
health
Standard automated perimetry (SAP)
Standard automated perimetry (SAP) is considered the 
gold standard for visual field assessment and monitoring of 
visual field loss, with RGC loss correlating with automated 
perimetry observations in glaucoma patients [145]. Param-
eters, such as the mean deviation (MD), pattern standard 
deviation (PSD), and glaucoma Hemifield test (GHT), have 
been used for many years. However, these global-indices-
based approaches have limitations, which include human 
error in estimating the rate of progression, the large number 
of visual field measurements required for trend-based anal-
ysis, and the large amount of information lost when com-
piling SAP data into a single integer of progression [26]. 
Attempts to overcome these limitations led to the develop-
ment of event-based and trend-based analysis techniques, 
such as guided progression analysis (GPA) and visual field 
index (VFI). GPA involves the comparison of each visual 
field assessment with a series of baseline tests, with progres-
sion defined as a binary outcome (progressor/non-progres-
sor). This technique requires fewer visual field tests (shorter 
follow-up time) than trend-based analysis techniques but 
is considered less reliable [75]. Alternative approaches to 
visual field analysis include the assessment of progression 
at each individual test location (Progressor) [180], or using 
structurally relevant test location clusters [8].
Classically glaucomatous visual field loss is described as 
loss of peripheral vision, however, a prospective evaluation 
of glaucoma patients’ visual symptoms suggests that early 
glaucomatous visual defects can be more complex, involv-
ing RGC loss in the central retina [78]. Observations such 
as these have led to a resurgence in interest in the role of 
central vision defects in glaucoma progression, particularly 
at the level of the macular [76]. This is problematic for 
SAP as although macular defects have long been reported 
in early stage glaucoma [6], the most commonly used SAP 
test (Humphrey 24-2 visual field test) utilizes points spaced 
6° apart [196], which neglects a large portion of the cen-
tral macula which has an approximate field diameter of 8° 
[76]. While the macula represents less than 2 % of the total 
retinal area, it is reported to contain over 30 % of the RGCs 
[34]. Together, these observations suggest that greater con-
sideration to macular defects should be considered for the 
diagnosis of glaucoma using SAP.
Optical coherence tomography (OCT)
Optical coherence tomography (OCT) is a non-invasive 
optical-imaging technology allowing cross-sectional imag-
ing of the eye in vivo. OCT was first introduced in 1991 
and utilizes low-coherence interferometry to generate a 
two-dimensional cross-sectional image of the retina [79]. 
The axial and lateral resolutions of OCT are decoupled, 
with the axial resolution depending on the coherence length 
of the laser light source and the lateral resolution a function 
the optical properties of the system, including patient pupil 
size [202].
Spectral-domain (SD) OCT is capable of scanning 
speeds up to 110 times faster than its predecessor, time 
domain (TD)-OCT [160]. SD-OCT employs a broadband 
light source and a high-speed spectrometer generating 
a mean imaging range ~3.0 μm in the air, a rapid sensi-
tivity fall-off (~6 dB/1.5 mm), and a 120 kHz scan rate, 
achieving image capture speeds of approximately 27,000 
A-scans/second with typical axial resolution of 6 µm [56]. 
The high axial resolution enables this technique to repro-
ducibly assess the thickness of retinal structures, includ-
ing the ability to longitudinally monitor retinal nerve 
fibre layer (RNFL) changes in clinical glaucoma. The 
high acquisition speeds of SD-OCT permit the collection 
of three-dimensional data sets for clinical use. Using this 
technique, volumetric assessment of structures, including 
the ONH and macular, can be achieved. To compensate for 
eye movement during imaging acquisition, OCT images are 
registered using reference images acquired using confocal 
scanning laser ophthalmoscope (cSLO) or OCT-mediated 
blood-vessel alignment [191].
Recent advances in OCT technology have led to the 
development of so-called functional-OCT technologies 
[99], including Doppler OCT for the assessment of reti-
nal blood flow and polarisation OCT for the assessment 
of birefringent tissues, such as ganglion cell axon densi-
ties [106]. Improvements to the underlying OCT technol-
ogy have led to the development of swept source (SS)-OCT 
[168], Adaptive Optics (AO)-OCT [126], and Frequency-
Domain (FD)-OCT [128]. With the resulting enhancements 
in image resolution through improvements in image acqui-
sition speed and compensation for wavefront aberrations 
caused by anterior ocular tissues, the resolution of this 
technique allows visualisation of individual cone photo-
receptors cells, RNFL bundles [126], and the thickness of 
RGC layers [128]. At present, individual RGCs cannot be 
visualised using OCT due to the near transparent nature of 
these cells.
Confocal scanning laser ophthalmoscopy (cSLO)
Confocal scanning laser ophthalmoscopy (cSLO) is pres-
ently the most extensively used retinal imaging technique, 
despite being first described over 35 years ago. cSLO 
instruments, such as the Heidelberg Retina Tomography 
III (HRT III; Heidelberg Engineering, Heidelberg, Ger-
many) instrument, incorporate a point laser light source 
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which scans the retina and a confocal pinhole aperture that 
acts to minimise scattered and reflected light outside the 
image focal-plane dramatically increasing lateral resolu-
tion (10 µm) versus fundus photography and enabling reti-
nal topographic imaging. cSLO has proven to be a useful 
and versatile tool for the assessment of geographic atrophy 
[158], epiretinal membrane characteristics [149], drusen 
deposits [159], fluorescein/indocyanine green angiogra-
phy [89], RPE [28], retinal nerve fibre layer thickness, and 
optic nerve head morphology [95]. Despite the wide-range 
of applications for which cSLO imaging is used, this tech-
nique has several well-documented limitations, including 
impaired imaging in the presence of lens and corneal opaci-
ties, small pupils, and limited axial resolution (300 µm) 
[42]. To address these limitations, several adaptations to 
cSLO imaging have been developed which are described in 
the following sub-sections.
Adaptive optics
Adaptive optics (AO) presents a technique which can be 
combined with the conventional cSLO- and OCT-imaging 
modalities to sufficiently enhance the resolution of cSLO 
imaging to resolve individual cells, with current practi-
cal lateral and axial resolutions of 2.5 and 100 µm, [152] 
compared to that of conventional cSLO systems which are 
typically 10 and 300 µm, respectively. Resolution is lim-
ited by optical aberrations in ocular tissues and can exhibit 
a large variation between individual patients and over time 
[117].
Adaptive optics (AO) was first described by Horace Bab-
cock in 1953 and involves measuring wavefront distortions 
caused by optical aberrations (such as atmospheric distur-
bance in ground-based astronomy or corneal and lens effects 
in retinal imaging) and using a device, such as a deform-
able mirror or liquid crystal array, to compensate for these 
distortions [7]. While this technology initially found use for 
military and astronomical observations, Dreher et al. demon-
strated that AO could also be used to enhance the resolution 
of cSLO retinal imaging in 1989 [44]. Limitations of cor-
recting ocular aberrations using AO include the number of 
adjustable elements in the deformable mirror and the deflec-
tion range of the surface [11]. Today, many AO systems 
employ microelectromechanical system (MEMS) wavefront 
correction techniques, which are lower in cost than pie-
zodriven mirrors and spatial light modulators [11].
Since this time AOSLO systems have been successfully 
used to visualise a variety of ocular tissues, including reti-
nal nerve fibre bundles and photoreceptors at the single-cell 
resolution [151, 153]. Despite the significant progress in 
visualising some retinal cell types using AOSLO systems, 
the label-free visualisation of RGCs using this technique 
has not yet been achieved. This is because the nerve fibre 
and ganglion cell layers are approximately 10–20 µm in 
thickness, which is smaller than the theoretical axial res-
olution limit of current generation AOSLO systems of 
33 µm [150]. Improvement in AOSLO axial resolution to 
less than 10 µm is required for the label-free imaging of 
individual RGCs using AOSLO [139]. Suggested improve-
ments to AOSLO systems to reduce axial resolution below 
the required 10 µm threshold include imaging with longer 
wavelengths of light which exhibit greater depth of tis-
sue penetration, reducing the size of the confocal pinhole 
aperture while overcoming associated diffraction artefacts 
and improving the signal-to-noise ratios through averaging 
of multiple scans while mitigating eye-movement effects 
[151].
Contrast agents for the in vivo visualisation of healthy 
RGCs
Despite the many applications of cSLO imaging, the visu-
alisation of RGCs remains extremely difficult due to their 
almost transparent nature rendering them virtually invisible 
to optical systems. The development of fluorescent mark-
ers of retinal cells has been performed to enhance RGC and 
cellular contrast for visualisation by cSLO imaging. Due 
to the central role of RGC loss in glaucoma pathology, it 
is perhaps not surprising that recent advances in diagno-
sis of this condition have focused on the development of 
novel techniques to visualise RGCs. Efforts have included 
coupling RGC specific contrast agents with cSLO-imaging 
techniques or the development of novel cSLO-imaging 
modalities to enhance RGC visualisation in a label-free 
system. The following sections give an overview of recent 
developments in each of these fields.
Preclinically, several techniques for labelling healthy 
RGCs in vivo have been described, including the use of 
transgenic models expressing fluorescent cell-specific pro-
teins, the utilisation of retrograde fluorescent tracers, and 
intravitreal administration of contrast agents. Several trans-
genic models expressing RGC specific fluorescent proteins 
have been described in rodents, including Thymocyte dif-
ferentiation antigen 1 (Thy1) [108]. Although transgenic 
rodent models can achieve labelling efficiencies of ~80 % 
of total (Fluorogold positive) RGCs, the specificity of 
labelling using this technique is limited as a result of co-
labelling of displaced amacrine cells and microglia due 
to phagocytosis of fluorescently labelled apoptotic RGCs 
[185]. Despite these limitations, transgenic models express-
ing RGC specific fluorescent proteins are increasingly 
being used to monitor the rate of RGC loss and investigate 
behaviour of RGC subtypes using established glaucoma 
models [48].
Retrograde labelling of RGCs involves the application of 
dyes, such as Fluorogold, carbocyanine dyes (DiAsp, DiI, and 
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DiO), and rhodamine-labelled dextrans typically to the visual 
centres in the brain, such as the lateral geniculate nucleus [67] 
or superior colliculus [29], where they undergo retrograde 
axonal transport to specifically label RGC soma in the retina 
[173]. Retrograde RGC labelling is a commonly used tech-
nique to visualise RGCs in experimental glaucoma models 
[133], however, due to the invasive nature of dye administra-
tion, this form of retrograde RGC labelling is presently unsuit-
able for clinical translation. Additional criticisms of retrograde 
labelling of RGCs include incomplete labelling of the RGC 
population and reduced labelling specificity due to phagocytic 
uptake of injured but labelled RGCs by microglia and mac-
rophages [185]. Recent attempts to address these criticisms 
have included the application of retrograde tracers to tran-
sected optic nerves, which has resulted in high RGC labelling 
efficiency (between 96 and 100 %) [155]. In addition, recent 
observations suggest that the application of the retrograde 
tracers Fluorogold or Granular Blue directly to the intact rat 
optic nerve can result in efficient retrograde labelling of RGCs 
without damaging the optic tract, potentially increasing the 
likelihood of this technique finding clinical utility [112].
Intravitreal administration of fluorescent markers, such 
as labelled cholera toxin subunit-B (CTB), has been used 
to evaluate RGC populations in mice up to 100 days post 
injection [165]. CTB is an attractive label due to the low 
cellular toxicity and previous safe systemic administra-
tion to patients [156]. Although CTB is not RGC specific, 
labelling both RGCs and amacrine cells, as the number of 
amacrine cells is minimally affected in glaucoma models 
[96] this may not impact the clinical utility of this technique 
for disease monitoring. The use of intravitreal injection to 
administer the CTB contrast agent does, however, remain 
a hurdle to successful clinical translation. Although intra-
vitreal injection of anti-vascular endothelial growth factors 
(anti-VEGFs) has revolutionised the treatment of common 
eye disorders, such as neovascular age-related macular 
degeneration [52], intravitreal injections remain an invasive 
administration technique unsuitable for the administration 
of contrast agents in the clinic due to the small but serious 
risk of side effects [52]. Interestingly, the ability of CTB 
conjugates to act as retrograde tracers may ultimately permit 
retrobulbar delivery of this contrast agent into the orbital fat 
for retrograde labelling of healthy RGCs in patients.
Contrast agents for the in vivo visualisation of apoptotic 
RGCs
In addition to cellular labelling, a major advance has been 
the in vivo visualisation of cellular processes. Apoptosis 
imaging has been advocated by our group and others using 
annexin A5 and caspase markers. Annexin A5 electro-
statically interacts with negatively charged lipids, includ-
ing phosphatidylserine, in the presence of divalent cations 
such as calcium [125]. This is significant as in heathy cells 
phosphatidylserine is predominantly localized to the inner 
leaflet of the plasma membrane, however, during apopto-
sis downregulation of flippase activity coupled with acti-
vation of scramblases collectively results in the exposure 
of phosphatidylserine on extracellular membrane leaflet of 
the apoptotic mammalian cell (Fig. 2) [109]. Fluorescently 
conjugated annexin A5 is a well-established tool for the 
detection of apoptotic cells in vitro (i.e. FITC-conjugated 
Annexin V [137]). More recently, Technetium-99 m (99 m 
Tc) radiolabelled annexin A5 has been used in vivo to detect 
apoptosis in over 30 clinical trials for a range of disorders, 
including acute cardiac allograft rejection, acute myocardial 
infarction, ischemic brain injury, cerebral hypoxia, breast 
cancer, lung cancer, lymphoma, sarcoma, and hepatitis 
[148]. Externalisation of phosphatidylserine is also reported 
in cells undergoing necroptosis, which can also be identified 
using fluorescently conjugated annexin A5 [137].
Our group has recently developed a technology called 
the detection of apoptotic retinal cells (DARC). DARC 
uses a fluorescent dye covalently conjugated to the pro-
tein annexin A5 in a 1:1 stoichiometry. It was first used to 
visualise apoptotic RGCs in experimental glaucoma in vivo 
using non-invasive wide-angle cSLO imaging [30]. Since 
this time, DARC has been successfully applied to differ-
ent experimental disease models and has been used to 
evaluate the neuroprotective effects of drug candidates and 
monitor the efficacy of therapeutic intervention [61]. A 
Phase I clinical trial of intravenously administered DARC 
(ISRCTN59484478) in healthy and glaucoma subjects has 
recently been completed with results to be published shortly.
TCapQ technology comprises a cell-penetrating Tat-
peptide conjugated to an effector caspase recognition 
sequence (DEVD), a quencher (QSY7), and a fluorophore 
(Alexa Fluor- 488) which is activated by caspase 3 and 7 
in the cytoplasm of pro-apoptotic cells [17]. In an NMDA-
induced rat model of glaucoma, intravitreally administered 
TCapQ was found to enable visualisation of apoptotic 
RGCs using cSLO, a result confirmed by ex vivo TUNEL 
staining [143]. Since this time, an improved cell-penetrat-
ing caspase-activatable probe, KcapQ, has been devel-
oped with reduced toxicity [121]. KcapQ incorporates an 
improved cell-penetrating peptide sequence (KKKRKV), 
is reported to exhibit a greater sensitivity to effector cas-
pases, and a greater quenching efficiency between the fluo-
rophore-quencher pair than TcapQ [121]. This technology, 
however, remains in the preclinical development stage.
Assessment of glaucomatous change in the brain using 
MRI
Having previously considered the role of RGCs in glau-
coma progression, this section of the review will evaluate 
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the evidence for the involvement of the LGN and visual 
cortex in glaucomatous degeneration.
Studies of glaucomatous degeneration in the brain were 
originally derived from experimental monkey models of 
glaucoma, which identified trans-synaptic degeneration at 
the site of the LGN and V1 in response to increased IOP and 
optic nerve damage [201]. Histological observations from 
monkey models were supported by those from post-mortem 
human studies that reported a significant reduction in M-cell 
density in five glaucoma patients compared to controls 
[25]. A subsequent post-mortem clinicopathological case-
report described degeneration of the intracranial optic nerve, 
LGN and visual cortex in a 79 year old glaucoma patient 
[69]. Since this time, the advent of non-invasive brain-
imaging techniques, such as Magnetic Resonance Imaging 
(MRI), has led to a rapid growth in studies investigating 
the involvement of the visual pathway in glaucoma pathol-
ogy. Structural MRI studies have revealed a significantly 
shorter optic chasm height and reduced optic nerve diameter 
in glaucoma patients versus normal controls [203]. Neuro-
degenerative changes in the LGN, as evidenced by reduc-
tion in LGN height and volume, is also reported in POAG 
patients using voxel-based morphometry and diffusion ten-
sor imaging, with some evidence emerging to suggest that 
the extent of atrophy may correlate with disease severity 
[183]. A reduced LGN volume is also reported in patients 
with NTG versus age-matched controls, which may indicate 
a shared pathology in the brain [203].
In addition to LGN atrophy, a reduction in volume of the 
optic radiations and primary visual cortex is documented 
in patients with POAG [183]. There is some evidence to 
suggest that a loss of grey matter density occurs in the cal-
carine sulcus and primary visual cortex in response to pro-
longed sensory deprivation (AMD and glaucoma patients 
versus age-matched controls) [14]. More recent stud-
ies have reported inconsistencies in grey matter density 
and glaucoma pathology [110, 188]. This is suggested to 
occur due to differences in the disease progression between 
POAG patients included in these studies [110], with an 
early increase in the grey matter density reported to pre-
cede a decline later in the disease process [188]. The early 
increase in grey mater may be a result of inflammatory pro-
cesses, such as microglia activation, which is reported in 
the human glaucomatous ONH [199] and throughout the 
anterior visual pathway in rodent glaucoma models [45].
Manganese (II) chloride has been employed as a con-
trast agent for diffusion tensor MRI imaging owing to Mn2+ 
ions being paramagnetic and acting to shorten the spin lat-
tice relaxation time constant of tissues in which it accumu-
lates [118]. Mn2+ contrast agents are particularly useful for 
visualisation of the visual pathway due to its ability to act 
as a calcium analogue and enter neurons via voltage gated 
Ca2+ channels. Once in the cytoplasm, Mn2+ ions are shut-
tled along axons by microtubual dependent axonal transport 
processes and can cross synaptic junctions to neighbour-
ing neurons [118]. To date, Mn2+ contrast MRI has been 
utilised to demonstrate significant anatomical age-related 
differences in rodent models of glaucoma and healthy con-
trols, including an increase in ocular perimeter (15 vs. 3 %), 
an 8 % reduction in retinal layer thickness, and a negative 
Fig. 2  Overview of the DARC technology for the detection of apop-
totic retinal cells. a Fluorescently labelled annexin A5 (AnxV) pref-
erentially interacts with phosphatidylserine (purple) in a calcium-
dependent manner. Phosphatidylserine is predominantly localised 
to the inner leaflet of the plasma membrane of healthy retinal cells 
via the action of ATP dependent flippases. In apoptotic cells, phos-
phatidylserine is translocated to the outer membrane leaflet via the 
downregulation of flippase activity and activation of scramblases, 
which result in a net increase in phosphatidylserine externalisation. 
The binding of fluorescently labelled AnxV to this externalised phos-
phatidylserine permits the visualisation of apoptotic cells at a cellu-
lar resolution in vivo. b In vivo cSLO retinal image of a Dark Agouti 
rat with ocular hypertension (Morrison’s model) captured using a 
55° lens 2 h after intravitreal administration of fluorescently labelled 
AnxV (DARC). Apoptotic retinal cells can be clearly visualised as 
white spots
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correlation between optic nerve head width with axonal 
density (r = 0.62, P = 0.02) [20]. More recently, this tech-
nique has been employed for retinotopic mapping of the 
superior colliculus in Sprague–Dawley rats after partial 
optic nerve transection [23]. The authors demonstrate that 
reduced anterograde axonal transport can be effectively 
monitored to the sub-millimeter resolution using Mn2+ con-
trast MRI; however, the narrow range between diagnostic 
and toxic doses of Manganese (II) chloride will require the 
development of better tolerated alternatives (Mn-chelates) 
for the translation of this technology to the clinic.
Findings from functional MRI (fMRI) investigations 
also suggest that changes in the primary visual cortex cor-
relate with anterior visual pathway disease severity [167]. 
In POAG patients, Quing et al. (2010) and Gerente et al. 
(2015) used blood oxygen-dependent fMRI to demonstrate 
that POAG may lead to reduced cortical activity in the pri-
mary visual cortex, which correlates with disease severity 
[142]. Finally, recent resting-state functional MRI studies 
report alternations in the connectivity of the primary visual 
cortex and in connectivity between the primary and higher 
visual centres in POAG patients in response to RGC loss 
[35]. Care should be taken, however, when interpreting the 
results of fMRI studies given the extremely high false-posi-
tive rate recently associated with this technique [47].
Clinical relevance of glaucomatous brain changes
The observation that brain changes occur in glaucoma 
patients begs the question as to whether these changes 
precede or follow the well-established neurodegeneration 
of RGCs and their axons in the anterior visual pathway. 
Although the timeline of the natural history of brain changes 
in glaucoma is at present poorly described, observations of 
retrograde trans-synaptic degeneration in a variety of neuro-
degenerative diseases (including Alzheimer’s disease [114] 
and Multiple Sclerosis [59]), coupled with similarities in 
the pathology between glaucoma and Alzheimer’s disease 
may suggest retrograde trans-synaptic degeneration (Fig. 3) 
is responsible for RGC loss in glaucoma [141]. Some 
additional evidence to support this view can be derived 
from monkey models of ocular hypertension, which report 
that depravation of visual input via RGC loss is not solely 
responsible for degeneration of the visual pathway [71]. The 
prevailing view currently, however, is that the majority of 
glaucomatous degeneration of the posterior visual pathway 
is preceded by the degeneration of RGC axonopathy, imply-
ing anterograde trans-synaptic degeneration is responsible 
for glaucomatous brain changes (Fig. 3) [19].
While the high cost and limited accessibility to MRI 
facilities compared to ophthalmic examinations are likely 
to limit the utility of brain imaging as a front-line glaucoma 
diagnostic or monitoring tool as suggested elsewhere [111], 
the identification of neurodegeneration in the visual centres 
of the brain has important implications for the treatment of 
glaucoma. Emerging therapeutic interventions intended to 
restore vision in glaucoma patients, such as RGC transplan-
tation [178] and artificial retinal implants [120], will need 
to consider the condition of the posterior visual pathway 
as a confounding factor in the efficacy of therapeutic inter-
ventions, including the extent of regeneration of the brain’s 
visual centres in response to reanimation of the anterior 
visual pathway [141]. The observation of glaucomatous 
neurodegeneration in the brain also has implications for 
assessing the efficacy of neuroprotective therapies, suggest-
ing that the focus of these therapies should be extended to 
include the whole CNS and that the visual centres of the 
brain should be included as endpoints in studies of thera-
peutic efficacy in glaucoma trials [141].
To that end, Weber et al. [187] recently reported that sup-
plementing intravitreal BDNF therapy with injection directly 
to the visual cortex resulted in a significant enhancement 
in RGC survival in a feline optic nerve crush injury model 
versus intravitreal administration of BDNF alone. However, 
Dekeyster et al. [37] found that viral-vector-mediated upreg-
ulation of BDNF in the superior colliculus alone was unable 
to elicit a significant neuroprotective activity in murine mod-
els of optic nerve crush or laser-induced ocular hypertension. 
The authors suggest their observations to be a result of viral-
vector-induced neurotrophin desensitisation, resulting in a 
failure of BDNF expressed in the superior colliculus to reach 
the retina via retrograde transport in both healthy mice and 
injury models. A possible explanation for this is that viral-
induced expression of BDNF acts to reduce TrkB-FL expres-
sion, a prerequisite for vesicular retrograde transport of this 
protein. In addition to its neuroprotective activity, however, 
overexpression of BDNF is increasingly recognised to 
increase susceptibility to excitotoxicity [131] and downregu-
lation of TrkB-FL is reported in response to excitotoxicity 
[179]. Viral-induced over production of BDNF may promote 
excitotoxicity vulnerability, precluding the neuroprotective 
effects of this agent. This finding has important implications 
for the growing range of disorders for which recombinant 
BDNF therapy is being investigated [115].
Finally, upregulation of BDNF secretion and TrkB-activa-
tion has been suggested as a potential mechanism underlying 
the ability of transcranial direct current stimulation to enhance 
neuronal function in mice [58]. Alternating current stimulation 
was recently demonstrated in an interventional randomised 
clinical trial to result in a significant mean improvement in 
visual field versus sham-treatment controls [24.0 % (n = 45) 
vs. 2.5 % (n = 37)] in patients with optic neuropathy, which 
persisted at 2 month follow-up [60]. Together, these studies 
provide tantalising evidence to suggest that future glaucoma 
therapies lie beyond the retina as the primary site of action, 
instead targeting the whole visual pathway.
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Summary
A better understanding of the mechanisms underlying RGC 
loss is essential to the development of novel therapeutic inter-
ventions to slow or prevent glaucomatous degeneration. The 
growing recognition that glaucoma is a disease of the whole 
visual pathway and not just the retina has led to a recent expan-
sion in the number and variety of techniques with the potential 
to permit the diagnosis of disease before onset of visual field 
defects. The difficulty of direct visualisation of RGCs in the 
retina has limited the early diagnosis of glaucoma, as consider-
able loss of RGCs occurs before disease symptoms manifest. 
The expense of brain-imaging technologies, recent controver-
sies regarding the validity of fMRI investigations, and sugges-
tion that brain changes occur downstream of those in the optic 
nerve and retina suggest that while these technologies are likely 
to provide interesting mechanistic insights into the disease pro-
cess, they are unlikely to be adopted for the purpose of early 
diagnosis or screening of disease in the population. Progress 
towards the clinical translation of RGC specific contrast agents, 
including the DARC technology, therefore provides the most 
likely early diagnostic screening tool for glaucoma in the clinic. 
Finally, the increasingly recognised overlap in the mechanisms 
of neuronal loss in neurodegenerative disease suggests that a 
better understanding of glaucoma could inform the develop-
ment of novel treatment paradigms for other neurodegenerative 
disorders (and vice versa), with recent studies providing tanta-
lising evidence to suggest that the future of glaucoma therapies 
lie beyond the retina as the primary site of action, instead tar-
geting the whole visual pathway.
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